$NWBO: ATL-DC IS DCVax-L - part 1.
ATL-DC is DCVax-L.
This plain fact, that the main ingredient in two combo trials at UCLA, one - the SPORE 1 project with Mercks Keytruda - and two - the 14 year long combo trial with poly-iclc, which has just reached its primary end clinical date trial a month ago, is the most refuted one by, what we all known by "fudders".
A generic term for a dendritic cell vaccine used in these two combo trials, is mentioned in the clinical trials descriptions, but using a minimum of effort, it is very easy to deduce, that this ingredient is the same as NWBOs DCVax-L vaccine.
Though, people with an incentive to ignore or refute evident facts - due to them being either paid to do so, or by being short invested in NWBO and with an interest, that the share price drops - HAVE to insist keeping on denigrating themselves, refuting the unrefutable, because the extreme efficacy already shown by Linda Liau in these combo trials, shows the unfathomable potential of DCVax-L. And if ATL-DC in these combo trial is DCVax-L, then the following amount of research done at the UCLA in parallel with the DCVax-L P3 trial, have made use of so many resources and money, that one can not rationally assert, that DCVax-L is ANYTHING but a success.
But let's dive in and let's just play the trumph card. That Linda Liau during a webinar with Al Musella in december 2022 unequivocally stated, that ATL-DC used in UCLAs combo trials. The webinar
This is the excerpt of the transscript:
The webinar presentation was pulled from the internet shortly after, Al Musella stating someone "made him". The Q and A in it, contained explosive due diligence and still it is not known, who actually instigated the removal. Several sources downloaded it though, so it is still very much, possible to confirm.
Doctor Timothy Cloughesy from UCLA ALSO said, ATL-DC is DCVax-L during a webinar
Who is ALSO the principal investigator in the SPORE 1 UCLA combo trial with DCvax-L and Keytruda.
https://classic.clinicaltrials.gov/ct2/show/NCT04201873
He's also a part of the team, involced in the research leading to an upcoming Nature article about the combo trial with DCvax-L and Poly-iclc.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3568250/
Take a look at this video by Dr. Cloughesy at UCLA, then go to the 1:30 mark to see that DCVax (ATL-DC) is the dendritic cell vaccine that UCLA uses in combination with a PD-1 inhibitor (Pembrolizumab / Keytruda).
Then go to the 31:10 mark to see what vaccines are used by UCLA to get the immune cell to the tumor to fight the tumor. The only dendritic cell listed is DCVax.
That correlates with this PDF from April 2022, where Liau and Prins are mentioned in the same SPORE 1 project and with DCVax-L explicitly mentioned.
One should look further into the research Robert Prins has done for UCLA, which not least has led to an upcoming Nature article with DCVax-L and poly-iclc, currently in review.
UCLA is even directly mentioning their use of DCvax-L at their own website
https://www.uclahealth.org/cancer/cancer-services/brain-tumor/about-us
https://www.uclahealth.org/cancer/cancer-services/brain-tumor/treatments/biologics
https://www.uclahealth.org/cancer/cancer-services/brain-tumor/research-clinical-trials
https://www.uclahealth.org/news/fda-approval-brain-cancer-alzheimers
Let's zoom in on that:
Which ends the part 1 of the "ATL-DC IS DCvax-L" article.
In part 2, we will look into Robert Prins' work at UCLA on the combo trials and how it is glaringly obvious, that DCVax-L is the main ingredient in two pivotal combo trials against gbm.